e-learning
resources
Munich 2006
Wednesday 06.09.2006
Epidemiological and clinical aspects of tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The role of serum rifampicin level on antituberculosis treatment outcome
M. Z. Guler, E. Macit, B. Baktik, H. Gul, B. Ciftci, H. Yaman, E. Unsal, Y. Erdogan, S. Saygi (Ankara, Turkey)
Source:
Annual Congress 2006 - Epidemiological and clinical aspects of tuberculosis
Session:
Epidemiological and clinical aspects of tuberculosis
Session type:
Electronic Poster Discussion
Number:
4890
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Z. Guler, E. Macit, B. Baktik, H. Gul, B. Ciftci, H. Yaman, E. Unsal, Y. Erdogan, S. Saygi (Ankara, Turkey). The role of serum rifampicin level on antituberculosis treatment outcome. Eur Respir J 2006; 28: Suppl. 50, 4890
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Related content which might interest you:
Efficacy of anti-tuberculosis therapy with INH, RIF and Bedaquiline in mice with different genetic susceptibility to the infection
Source: International Congress 2019 – Tuberculosis: from basic science to patient care
Year: 2019
In vitro susceptibility to rifampin and ethambutol and treatment outcome in MAC lung disease
Source: International Congress 2018 – The global impact of bronchiectasis and nontuberculous mycobacteria (NTM)
Year: 2018
The role of moxifloxacin in tuberculosis therapy
Source: Eur Respir Rev 2015; 25: 19-28
Year: 2016
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004
Patient choice promotes adherence in preventive treatment for latent tuberculosis
Source: Eur Respir J 2007; 30: 728-735
Year: 2007
The efficacy of treatment of patients with drug resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB
Source: Eur Respir J 2009; 33: 581-585
Year: 2009
Treatment outcome of combination antibiotic therapy including clarithromycin for
Mycobacterium avium
complex pulmonary disease
Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis
Year: 2010
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007
Higher adverse drug reactions but better completion rate of twelve-dose weekly rifapentine plus isoniazid comparing with nine-month daily isoniazid for latent tuberculosis infection among patients under maintenance dialysis
Source: Virtual Congress 2020 – Tuberculosis: part 1
Year: 2020
Evaluation of therapeutic response in isoniazid resistant TB
Source: Eur Respir J 2006; 28: Suppl. 50, 846s
Year: 2006
Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients
Source: Eur Respir J 2016; 48: 1237-1239
Year: 2016
Efficacy and safety of levamisole as an immunomodulator in the treatment of drug resistant tuberculosis
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
A study of role of rifabutin as an adjuvant in management of cases with multi-drug resistant pulmonary tuberculosis
Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis
Year: 2007
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy
Source: Eur Respir J 2001; 17: 641-646
Year: 2001
A UK cost comparison of amikacin therapy with bedaquiline, for drug resistant tuberculosis
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Long-term results of drug resistant tuberculosis treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 378s
Year: 2006
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid
Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept